Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Dice Therapeutics Inc (DICE)

Dice Therapeutics Inc (DICE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,269,609
  • Shares Outstanding, K 47,731
  • Annual Sales, $ 0 K
  • Annual Income, $ -83,890 K
  • 60-Month Beta 1.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.37
Trade DICE with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.18
  • Most Recent Earnings $-0.54 on 05/11/23
  • Next Earnings Date 08/10/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate -0.69
  • Number of Estimates 3
  • High Estimate -0.64
  • Low Estimate -0.75
  • Prior Year -0.55
  • Growth Rate Est. (year over year) -25.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.42 +2.43%
on 07/10/23
47.90 -0.73%
on 08/02/23
+1.15 (+2.48%)
since 07/07/23
3-Month
29.58 +60.75%
on 06/05/23
47.90 -0.73%
on 08/02/23
+9.44 (+24.77%)
since 05/08/23
52-Week
15.08 +215.32%
on 08/31/22
47.90 -0.73%
on 08/02/23
+27.81 (+140.88%)
since 08/08/22

Most Recent Stories

More News
BiondVax Pharmaceuticals (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs

BiondVax (NASDAQ: BVXV), a biotechnology company that recently signed an exclusive worldwide license to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting...

BVXV : 1.3600 (+3.82%)
LLY : 885.55 (-0.62%)
DICE : 47.55 (+0.06%)
Why These 3 Large Caps Are Bucking the August Slump

The three largest S&P 500 outperformers of August are tacking on gains in a weak market, making them intriguing momentum plays to watch for the rest of 2023.

LLY : 885.55 (-0.62%)
ANET : 390.11 (+0.13%)
GPN : 98.19 (+0.54%)
DICE : 47.55 (+0.06%)
SGTX : 22.47 (-2.56%)
PYPL : 77.31 (-0.17%)
SQ : 65.64 (+0.89%)
EFX : 293.50 (+0.06%)
EVOP : 33.99 (+0.38%)
Lilly Completes Acquisition of DICE Therapeutics

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The...

LLY : 885.55 (-0.62%)
DICE : 47.55 (+0.06%)
M&A Activity, Sales of Anti-IL-17 Drugs Suggest Upside Potential for BiondVax Pharmaceuticals (NASDAQ: BVXV)

According to Goldman Sachs Research, the global pharmaceutical industry is sitting on about $700 billion in dealmaking firepower, expected to fuel M&A-driven growth as companies look to revamp their intellectual...

BVXV : 1.3600 (+3.82%)
GS : 486.10 (-1.20%)
LLY : 885.55 (-0.62%)
DICE : 47.55 (+0.06%)
Lilly Announces Extension of Tender Offer to Acquire DICE

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and...

LLY : 885.55 (-0.62%)
DICE : 47.55 (+0.06%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DICE, QUOT, TALS, CFMS

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

DICE : 47.55 (+0.06%)
QUOT : 3.99 (unch)
TALS : 27.20 (-0.73%)
CFMS : 2.26 (unch)
Moore Kuehn Encourages EMAN, NETI, PDCE, DICE, and NETI Investors to Contact Law Firm

/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...

EMAN : 2.07 (+2.99%)
NETI : 11.33 (+0.09%)
PDCE : 73.85 (-0.27%)
DICE : 47.55 (+0.06%)
IMPORTANT ALERT: Halper Sadeh LLC Investigates DICE, IMNM, AJX

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

DICE : 47.55 (+0.06%)
IMNM : 13.43 (-0.52%)
AJX : 3.24 (-1.52%)
Why Shares of Ventyx Biosciences Rose Monday

The company has several promising autoimmune therapies.

DICE : 47.55 (+0.06%)
RXDX : 199.92 (+0.09%)
MRK : 110.18 (-1.70%)
LLY : 885.55 (-0.62%)
VTYX : 2.06 (-2.37%)
IMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, DICE, NEX, NETI

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

TALS : 27.20 (-0.73%)
DICE : 47.55 (+0.06%)
NEX : 10.61 (+0.95%)
NETI : 11.33 (+0.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

DICE Therapeutics Inc. is a biopharmaceutical company. Its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 48.14
2nd Resistance Point 47.98
1st Resistance Point 47.77
Last Price 47.55
1st Support Level 47.40
2nd Support Level 47.24
3rd Support Level 47.03

See More

52-Week High 47.90
Last Price 47.55
Fibonacci 61.8% 35.36
Fibonacci 50% 31.49
Fibonacci 38.2% 27.62
52-Week Low 15.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar